Kyverna Therapeutics Names Emany Audit Chair, Adds Karuna Founder Miller
Kyverna Therapeutics named Sravan K. Emany as Audit Committee Chair and added Andrew Miller, Ph.D., to its Board of Directors to strengthen capital strategy and clinical development ahead of commercialization. Emany brings CFO experience at Beam Therapeutics, while Miller co-founded Karuna Therapeutics and led R&D through its $14B sale.
1. Board Appointments
Kyverna Therapeutics appointed Sravan K. Emany as Audit Committee Chair and Andrew Miller, Ph.D., as a new director to bolster financial oversight and clinical development governance. These appointments coincide with Dan Spiegelman’s transition from the audit chair role and aim to support Kyverna’s advancement toward commercializing its autoimmune CAR T-cell therapies.
2. Executive Backgrounds
Sravan Emany brings CFO tenures at Beam Therapeutics and Ironwood Pharmaceuticals plus extensive investment banking experience at Bank of America and Goldman Sachs, enhancing the company’s capital markets strategy. Andrew Miller co-founded Karuna Therapeutics, led its R&D through a $14B acquisition by Bristol Myers Squibb, and adds deep expertise in clinical development and product approval to accelerate Kyverna’s autoimmunity pipeline.